TriSalus Life Sciences (TLSI) Non-Current Debt (2024 - 2026)

TriSalus Life Sciences has reported Non-Current Debt for 3 years, with the latest figure at $33.1 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Debt rose 4.35% year-over-year to $33.1 million; the trailing twelve-month figure through Mar 2026 stood at $33.1 million (up 4.35% YoY), and the FY2025 full-year result was $33.0 million, up 49.64% from the prior year.
• Non-Current Debt for Q1 2026 stood at $33.1 million, roughly flat from $33.0 million in the prior quarter.
• The five-year high for Non-Current Debt was $33.1 million in Q1 2026, with the low at $21.3 million in Q2 2024.
• Historically, Non-Current Debt has averaged $28.5 million across 3 years, with a median of $32.0 million in 2025.
• Annual changes were most pronounced in 2025 — Non-Current Debt jumped 51.62% — and 2026, when it increased 4.35%.
• TriSalus Life Sciences' Non-Current Debt stood at $22.1 million in 2024, then soared by 49.64% to $33.0 million in 2025, then advanced by 0.1% to $33.1 million in 2026.
• The last three Non-Current Debt figures came in at $33.1 million (Q1 2026), $33.0 million (Q4 2025), and $32.8 million (Q3 2025), per Business Quant data.